Payment overview · 2025
General Payments
$2,291.04
94 reported records · 20 companies
Healthcare provider profile · identity verified
Jesslyn Perry, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BUFFALO, NY · NPI 1205860186
Verified facts
What the public records show
CMS Open Payments records show Jesslyn Perry, M.D. received $2,291.04 in general payments during 2025 across 94 reported records.
Exact Sciences Corporation accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 403 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $290.29 | 12.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $279.02 | 12.2% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.39 | 8.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.04 | 8.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $188.49 | 8.2% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $157.30 | 6.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.50 | 6.3% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $129.33 | 5.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.89 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.95 | 5.0% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $104.78 | 4.6% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.94 | 2.9% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $55.61 | 2.4% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $47.15 | 2.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $46.95 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.26 | 1.8% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $38.33 | 1.7% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $27.39 | 1.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.79 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.64 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,291.04 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $290.29 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.93 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $188.49 | 11 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $157.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $129.33 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.82 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $124.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $114.95 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $109.50 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.46 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.46 | 11 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $104.78 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.15 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.94 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $55.61 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $47.15 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $47.15 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $38.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 137 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 403 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
403 | 106 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 296 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 739 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 622 | 183 |
| Gabapentin | Gabapentin | 616 | 168 |
| Omeprazole | Omeprazole | 481 | 125 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 403 | 106 |
| Lisinopril | Lisinopril | 342 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 102 |
| Benazepril Hcl | Benazepril Hcl | 329 | 99 |
| Metformin Hcl | Metformin Hcl | 284 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 59 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 227 | 59 |
| Potassium Chloride | Potassium Chloride | 223 | 53 |
| Famotidine | Famotidine | 217 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 58 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 189 | 63 |
| Baclofen | Baclofen | 181 | 47 |
| Ibuprofen | Ibuprofen | 181 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 64 |
| Clonidine Hcl | Clonidine Hcl | 171 | 44 |
| Furosemide | Furosemide | 165 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 47 |
| Sertraline Hcl | Sertraline Hcl | 157 | 36 |
| Jardiance | Empagliflozin | 155 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 36 |
| Spironolactone | Spironolactone | 142 | 39 |
| Eliquis | Apixaban | 137 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 40 |
| Ozempic | Semaglutide | 124 | 37 |
| Prednisone | Prednisone | 123 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 121 | 27 |
| Naproxen | Naproxen | 121 | 31 |
| Alendronate Sodium | Alendronate Sodium | 120 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 32 |
| Carvedilol | Carvedilol | 118 | 31 |
| Losartan Potassium | Losartan Potassium | 114 | 38 |
| Montelukast Sodium | Montelukast Sodium | 110 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 35 |
| Methocarbamol | Methocarbamol | 99 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 32 |
| Trulicity | Dulaglutide | 93 | 19 |
| Allopurinol | Allopurinol | 92 | 27 |
| Trazodone Hcl | Trazodone Hcl | 88 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 82 | 28 |
| Buspirone Hcl | Buspirone Hcl | 81 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 80 | 26 |
| Nifedipine Er | Nifedipine | 76 | 21 |
| Farxiga | Dapagliflozin Propanediol | 75 | 22 |
| Azithromycin | Azithromycin | 71 | 64 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 66 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 15 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Levetiracetam | Levetiracetam | 63 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 62 | 22 |
| Rybelsus | Semaglutide | 60 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 16 |
| Hydrocortisone | Hydrocortisone | 57 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 20 |
| Irbesartan | Irbesartan | 52 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 47 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Linzess | Linaclotide | 46 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Pregabalin | Pregabalin | 44 | 19 |
| Amoxicillin | Amoxicillin | 41 | 38 |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 38 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 11 |
| Nystatin | Nystatin | 32 | 12 |
| Ramipril | Ramipril | 32 | 12 |
| Nitroglycerin | Nitroglycerin | 31 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 12 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 11 |
| Ketoconazole | Ketoconazole | 26 | 12 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Epinephrine | Epinephrine | 16 | 11 |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Risperidone | Risperidone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,291.04 · 94 records | Exact Sciences Corporation | ABRYSVO, ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Fluad, Flucelvax, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Natroba, Ozempic, PREVNAR 20, Rybelsus, SPINRAZA, Spinosad, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error